Press Releases Latest May 09, 2024 Theratechnologies Reports on its Annual Meeting of Shareholders Press Releases Year None202420232022202120202019201820172016201520142013 Feb 28, 2023 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management Feb 22, 2023 Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV Feb 16, 2023 Theratechnologies Announces Path to Resume TH1902 Clinical Development Feb 14, 2023 Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update Jan 04, 2023 Open Letter to Shareholders from CEO Paul Levesque Dec 01, 2022 Theratechnologies Announces Update from Ongoing TH1902 Study Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium Oct 03, 2022 Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population First page « Previous page ‹ … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page › Last page » Displaying 61 - 70 of 362
Feb 28, 2023 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
Feb 22, 2023 Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
Feb 14, 2023 Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
Oct 03, 2022 Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population